BUZZ — Australia's AdAlta surges as partner lands up to $120 million cell therapy deal

* Shares of AdAlta rise as much as 33.3% to A$0.0040, marking their biggest intraday pct gain since September 3 * Shares hit their highest level since September 4 * Biotech firm says its cell therapy manufacturing partner Oribiotech has signed a 10-year agreement worth up to US$120 million * Adds, deal will integrate Oribiotech's IRO automated manufacturing platform for cell therapies into production of an approved and commercialised cell therapy * 1AD up 16.7% so far this week, its strongest weekly move since August 17 * Nearly 14 million shares change hands, about 7.8x the 30-day average * YTD, stock up 16.7%, including session's moves (Reporting by Subhalakshmi Dey in Bengaluru) ((Subhalakshmi.Dey@thomsonreuters.com;)